Last Updated: Mar 2026
Best Tirzepatide Medications of 2026
Your Spring Slim-Down Starts Here
*Subject to Medvi's Terms of Service.
**Subject to Ro Terms of Service.
***Subject to Medvi's Refund Policy.
Tirzepatide is the name of the drug — it’s not a brand name, but the active pharmaceutical ingredient (API) used in medications designed for the treatment of type 2 diabetes and obesity.
Brand Names Based on Tirzepatide:
Mounjaro® – Developed by Eli Lilly, approved for type 2 diabetes.
Zepbound™ – Also developed by Eli Lilly, specifically FDA-approved for chronic weight management (obesity) as of late 2023.
Compounded Tirzepatide – Available through licensed compounding pharmacies in the U.S. under the supervision of a healthcare provider; these versions are not FDA-approved but may be prescribed when medically necessary.
Drug Class: Dual GIP and GLP-1 receptor agonist
Form: Injectable medication, administered subcutaneously (under the skin), typically once per week
Tirzepatide is a single-molecule drug that:
Mimics two natural gut hormones: GIP and GLP-1
These hormones regulate appetite, insulin secretion, and blood sugar levels
Unlike earlier GLP-1-only medications (like semaglutide in Ozempic®/Wegovy®), Tirzepatide targets two receptors:
GIP (glucose-dependent insulinotropic polypeptide)
GLP-1 (glucagon-like peptide-1)
This dual mechanism is why Tirzepatide is often called a "twin incretin" therapy — incretins are hormones that help regulate insulin and hunger responses.
Tirzepatide works by:
Increasing satiety (you feel full sooner and longer)
Reducing appetite
Slowing gastric emptying
Improving insulin sensitivity
Lowering glucagon levels, which reduces blood sugar production by the liver
This combination leads to:
Substantial weight loss
Improved blood sugar control
Reduced risk of type 2 diabetes and other cardiometabolic conditions
Tirzepatide is a standalone therapy — it is not combined with other medications like semaglutide or liraglutide in a single pen or formulation. However, it may be part of a comprehensive medical plan including:
A reduced-calorie diet
Physical activity
Additional medications, such as:
Metformin (for diabetes)
Blood pressure medications (if cardiovascular risks are present)
| Feature | Tirzepatide (Mounjaro®, Zepbound™) | Semaglutide (Ozempic®, Wegovy®) | Liraglutide (Saxenda®) |
|---|---|---|---|
| Receptor Targets | GLP-1 + GIP | GLP-1 only | GLP-1 only |
| Dosing | Weekly | Weekly(Ozempic®, Wegovy®) | Daily |
| Weight Loss Potential | 15–22% average | 10–15% average | 5–8% average |
| FDA-Approved for Weight Loss | Yes(Zepbound™) | Yes(Wegovy®) | Yes(Saxenda®) |
When starting a Tirzepatide-based medication like Mounjaro® or Zepbound™, most users can expect:
A gradual but noticeable weight loss within the first few weeks
Reduced appetite, earlier fullness, and fewer cravings
A more manageable way to stick to healthier eating habits
Clinical trials have shown average weight loss of 15% to 22% of total body weight when combined with a healthy diet and activity.
Additional benefits may include:
Lower blood sugar levels
More energy
Better metabolic health
Follow-ups with your healthcare provider are crucial to adjust dosage and ensure long-term success.
Disclaimer: This content was generated with AI, along with human verification.
Disclosures:
(*)The assessment made available on the Remedy Meds website does not create a doctor-patient relationship between the individual completing the assessment and Remedy Meds. Remedy Meds is not a provider of medical services. Remedy Meds acts primarily as a technology platform to connect you with professional healthcare providers who may be available to provide you with non-emergency care. Such providers include JMP Medical, OpenLoop Health, and certain other medical groups (collectively, the “Providers”). The Providers include a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety and have established exclusionary criteria to determine if an individual does not qualify for GLP-1s. Each Remedy Meds assessment will be reviewed by a Provider who will determine if the individual is eligible for GLP-1 medication and qualifies for a prescription. Provider clinicians retain the decision to prescribe compounded GLP-1s to patients.
All claims and benefits on this website refer to self-reported data from Remedy Meds customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from compounded medications found on the Remedy Meds platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and medical history.
We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Remedy Meds does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.
(**)Along with a reduced calorie diet and increased exercise. In a 68-week clinical study of Wegovy®, about 1 in 3 adults with obesity or with overweight and weight-related medical problems achieved 20% weight loss. Average weight loss achieved was 15%. Wegovy® is a registered trademark of Novo Nordisk A/S. Hims, Inc. is not affiliated with or endorsed by Novo Nordisk A/S.
